ArticleJournal of magnetic resonance imaging : JMRI2026
Preoperative Prediction of Pituitary Adenoma Consistency Using Synthetic MRI and Virtual Magnetic Resonance Elastography.
Article in Journal of magnetic resonance imaging : JMRI, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Editorial for "Preoperative Prediction of Pituitary Adenoma Consistency Using Synthetic MRI and Virtual Magnetic Resonance Elastography".Journal of magnetic resonance imaging : JMRI · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPituitary macroadenomas consistency affects surgical planning and may limit complete resection. Advanced MRI techniques, including virtual magnetic resonance elastography (vMRE) and synthetic MRI, may enable preoperative prediction of pituitary macroadenomas consistency. PURPOSE: To evaluate the feasibility of vMRE and synthetic MRI for preoperative prediction of pituitary macroadenomas consistency. STUDY TYPE: Prospective. POPULATION: Sixty-five patients with pituitary macroadenomas were prospectively enrolled (39 females; age = 49.02 ± 8.53 years). FIELD STRENGTH/SEQUENCE: 3.0 T; Diffusion-weighted imaging (DWI), vMRE imaging based on a turbo spin-echo sequence, and synthetic MRI using the MAGiC. ASSESSMENT: The tumor consistency was classified as either soft (n = 49) or hard (n = 16) by two neurosurgeons based on intraoperative findings. Apparent diffusion coefficient (ADC) values, contrast-enhanced T1 values, quantitative parameters (T1, T2, PD) derived from synthetic MRI, and vMRE stiffness values for pituitary macroadenomas were independently measured by two radiologists and were compared between two consistency groups. STATISTICAL TESTS: Intraclass correlation coefficients (ICCs) were used to evaluate the inter-reader agreement of MRI-derived quantitative parameters. Clinical and pathological characteristics and MRI-related parameters were compared between the two groups using the independent t-test or the Chi-square test. Predictive modeling was assessed using receiver-operating-characteristic (ROC) curve analysis and multivariable logistic regression, and their predictive performance was evaluated using the area under the curve (AUC). A p < 0.05 was considered statistically significant.
resultsCompared with soft groups, hard groups showed significantly lower T2 and ADC values and higher vMRE stiffness. Combined models of vMRE+ADC and ADC+T2 yielded AUCs of 0.830 and 0.797, respectively. The combination of vMRE, ADC, and T2 achieved the highest performance (AUC = 0.860). DATA
conclusionsThe integration of vMRE stiffness with ADC and T2 values derived from synthetic MRI demonstrated preliminary feasibility for assessing pituitary macroadenomas' consistency in this internally validated cohort, suggesting a promising multiparametric approach. EVIDENCE LEVEL: 2. TECHNICAL EFFICACY: Stage 2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.